Baseline demographic and clinical characteristics
| Characteristic . | N = 134 . |
|---|---|
| Median age (range), y | 66 (42-85) |
| Age, n (%), y | |
| ≥65 | 77 (57) |
| ≥75 | 27 (20) |
| Men, n (%) | 99 (74) |
| Diagnosis of CLL, n (%) | 132 (99) |
| ECOG performance status, n (%) | |
| 0 | 48 (36) |
| 1 | 82 (61) |
| 2 | 4 (3) |
| Bulky lymph nodes, n = 133, n (%), cm in diameter | |
| ≥5 | 52 (39) |
| ≥10 | 10 (8) |
| Rai risk classification (derived at screening), n (%)* | |
| Low | 0 |
| Intermediate | 38 (28) |
| High | 65 (49) |
| Missing | 31 (23) |
| Prior therapies, median (range) | 2 (1-13) |
| Cytopenia at baseline, n (%) | 92 (69) |
| ANC, ≤1500 µL | 28 (21) |
| Hemoglobin, ≤11.0 g/dL | 43 (32) |
| Platelet count, ≤100 000/µL | 65 (49) |
| Prognostic factor, n/N (%) | |
| Unmutated IGHV | 81/111 (73) |
| Chromosome 17p13.1 deletion | 27/116 (23) |
| Chromosome 11q22.3 deletion | 21/116 (18) |
| Complex karyotype, ≥3 abnormalities | 20/57 (35) |
| B2-microglobulin, >3.5 mg/L | 76/101 (75) |
| Characteristic . | N = 134 . |
|---|---|
| Median age (range), y | 66 (42-85) |
| Age, n (%), y | |
| ≥65 | 77 (57) |
| ≥75 | 27 (20) |
| Men, n (%) | 99 (74) |
| Diagnosis of CLL, n (%) | 132 (99) |
| ECOG performance status, n (%) | |
| 0 | 48 (36) |
| 1 | 82 (61) |
| 2 | 4 (3) |
| Bulky lymph nodes, n = 133, n (%), cm in diameter | |
| ≥5 | 52 (39) |
| ≥10 | 10 (8) |
| Rai risk classification (derived at screening), n (%)* | |
| Low | 0 |
| Intermediate | 38 (28) |
| High | 65 (49) |
| Missing | 31 (23) |
| Prior therapies, median (range) | 2 (1-13) |
| Cytopenia at baseline, n (%) | 92 (69) |
| ANC, ≤1500 µL | 28 (21) |
| Hemoglobin, ≤11.0 g/dL | 43 (32) |
| Platelet count, ≤100 000/µL | 65 (49) |
| Prognostic factor, n/N (%) | |
| Unmutated IGHV | 81/111 (73) |
| Chromosome 17p13.1 deletion | 27/116 (23) |
| Chromosome 11q22.3 deletion | 21/116 (18) |
| Complex karyotype, ≥3 abnormalities | 20/57 (35) |
| B2-microglobulin, >3.5 mg/L | 76/101 (75) |
ECOG, Eastern Cooperative Oncology Group.
Derived based on data collected at screening; patients with absolute lymphocyte count <5 × 109/L at screening were reported as missing.